Calithera Biosciences, Inc.

Informe acción OTCPK:CALA

Capitalización de mercado: US$97.4k

Salud financiera de hoja de balance de Calithera Biosciences

Salud financiera controles de criterios 4/6

Calithera Biosciences tiene un patrimonio de los accionistas total de $20.4M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $28.7M y $8.3M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$25.45m
PatrimonioUS$20.39m
Total pasivoUS$8.28m
Activos totalesUS$28.68m

Actualizaciones recientes sobre salud financiera

Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?

Aug 17
Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Dec 17
We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Aug 27
We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Recent updates

Calithera gains 16% as FDA awards Fast Track status for lung cancer candidate

Oct 03

Calithera rises 8% after HC Wainwright upgrades rating to buy

Aug 29

Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?

Aug 17
Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Dec 17
We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Aug 27
We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

The Upcoming Calithera Cystic Fibrosis Data Could Be Significant

Aug 03

Calithera Biosciences Investor Presentation - Slideshow

May 08

Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?

May 02
Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?

What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?

Mar 10
What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?

Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Jan 17
Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Calithera sinks as telaglenastat fails in kidney cancer study; lowers headcount

Jan 04

Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In Growth

Dec 13
Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In Growth

Calithera Biosciences Poised For Long-Term Success

Nov 25

Calithera Biosciences (CALA) Investor Presentation - Slideshow

Nov 06

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($26.6M) de CALA superan a sus pasivos a corto plazo ($7.4M).

Pasivo a largo plazo: Los activos a corto plazo de CALA ($26.6M) superan a sus pasivos a largo plazo ($894.0K).


Historial y análisis de deuda-patrimonio

Nivel de deuda: CALA está libre de deudas.

Reducción de la deuda: CALA no ha tenido ninguna deuda en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: Datos insuficientes para determinar si CALA tiene suficiente cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si CALA tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.


Descubre empresas con salud financiera